Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

(2015) Sungsoon Fang et al.   NATURE MEDICINE

A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism

(2015) Yang Xu et al.   Nature Communications

Lactobacillus acidophilus ATCC 4356 Prevents Atherosclerosis via Inhibition of Intestinal Cholesterol Absorption in Apolipoprotein E-Knockout Mice

(2014) Ying Huang et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Farnesoid X receptor: Acting through bile acids to treat metabolic disorders

(2014) Y. Zhang   DRUGS OF THE FUTURE

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

(2014) Changtao Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

Relative roles ofABCG5/ABCG8in liver and intestine

(2014) Jin Wang et al.   JOURNAL OF LIPID RESEARCH

Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans

(2013) Michael H. Davidson et al.   ATHEROSCLEROSIS

Bile acid receptors in non-alcoholic fatty liver disease

(2013) Yuanyuan Li et al.   BIOCHEMICAL PHARMACOLOGY

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis

(2013) Jiesi Xu et al.   HEPATOLOGY

Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor inLdlr−/−mice versus hamsters

(2013) Christophe Gardès et al.   JOURNAL OF LIPID RESEARCH

Lipidomic and metabolomic analyses reveal potential plasma biomarkers of early atheromatous plaque formation in hamsters

(2012) Mariona Jové et al.   CARDIOVASCULAR RESEARCH

Cholesterol Efflux and Atheroprotection

(2012) Robert S. Rosenson et al.   CIRCULATION

Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice

(2012) Bo Kong et al.   HEPATOLOGY

Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease

(2012) Geoffrey Porez et al.   JOURNAL OF LIPID RESEARCH

Reverse Cholesterol Transport Revisited

(2011) Gemma Brufau et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice

(2010) Katharina Slätis et al.   JOURNAL OF LIPID RESEARCH

Identification of Novel Pathways That Control Farnesoid X Receptor-mediated Hypocholesterolemia

(2009) Yanqiao Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/−and apoE−/−mice

(2009) Helen B. Hartman et al.   JOURNAL OF LIPID RESEARCH

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

(2009) Brenton Flatt et al.   JOURNAL OF MEDICINAL CHEMISTRY

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

(2009) Philippe Lefebvre et al.   PHYSIOLOGICAL REVIEWS